Contents
11 September 2019
Vol 11, Issue 509
Vol 11, Issue 509
Research Articles
- Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.
- Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation
Transcatheter aortic valve replacement alters a patient’s serum proteome, reversing valvular interstitial cell and cardiac myofibroblast activation.
- Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases
A DNA methylation–based classifier facilitates the differentiation of primary lung and metastatic head and neck cancer with diagnostic accuracy.
- Ventricular stroke work and vascular impedance refine the characterization of patients with aortic stenosis
High left ventricular stroke work and low vascular impedance predict better quality of life after valve intervention in patients with aortic stenosis.
- An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals
Infusions of anti-α4β7 monoclonal antibody did not affect plasma viral rebound in HIV-infected individuals who stopped antiretroviral drug therapy.
Editors' Choice
- Viruses teach T cells to tackle tumors
Oncolytic vaccinia virus expressing leptin enhances T cell clearance of melanomas.
- A trojan horse for treatment of brain tumors
Encapsulation and molecular targeting of therapeutic antibodies enhance CNS uptake and treatment efficacy in brain metastases.
- The hunt for a cure for Alzheimer’s disease receives a timely boost
Therapeutic strategy based on inhibition of tau hyperphosphorylation performs better than glutamate uptake by astrocytes in a mouse model.
About The Cover
ONLINE COVER Missing the Target. Although targeted treatment now plays a prominent role in oncology, many of the therapeutics in preclinical development never reach clinical approval. Lin et al. identified one potential cause for this problem, showing that some of the compounds in clinical development do not actually target the oncogenes they were originally thought to target. The authors also demonstrated how gene editing technology can help validate drug targets and determined the real target of one previously mischaracterized compound, suggesting that other drug candidates could require similar reclassification. [CREDIT: JULIA KUHL]
